For research use only. Not for therapeutic Use.
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment[1].
BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days’ oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33[1].
Catalog Number | I017137 |
CAS Number | 2241732-30-7 |
Synonyms | N-[3-[[6-(4-morpholin-4-ylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide |
Molecular Formula | C25H23N5O3 |
Purity | ≥95% |
InChI | InChI=1S/C25H23N5O3/c1-2-23(31)28-18-4-3-5-20(14-18)33-25-21-15-22(29-24(21)26-16-27-25)17-6-8-19(9-7-17)30-10-12-32-13-11-30/h2-9,14-16H,1,10-13H2,(H,28,31)(H,26,27,29) |
InChIKey | KLSYFSMLPFKXDQ-UHFFFAOYSA-N |
SMILES | C=CC(=O)NC1=CC(=CC=C1)OC2=NC=NC3=C2C=C(N3)C4=CC=C(C=C4)N5CCOCC5 |
Reference | [1]. HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. Patent WO2018145525 |